Using CDM® we will optimise patient selection, combine other clinical and patient demographics, and positively impact
trial costs and performance. CDM® can estimate a patient’s pathology disease stage using grey matter quality. We provide a likelihood that a
patient will progress to the next stage of disease within the next few years.
Previously inaccessible insights, unlocked by our proprietary technology, will enable more targeted, efficient
Unlocking novel insights for doctors from MRI scans enables earlier diagnoses and more personalised
treatment, giving hope to patients suffering from neurodegenerative diseases. Visualising brain changes
using CDM® can support communication between doctors, patients and their carers to help them understand the
We enable differential diagnoses by mapping neurodegenerative disease progression across different regions
of the brain, revealing different disease patterns based on cell structure. CDM® has identified different patterns of neurodegeneration in the brain in atypical Alzheimer’s disease
(posterior cortical atrophy) and fronto-temporal dementia.
We are tackling uncertainty in diagnosing neurodegenerative conditions, by giving clinicians confidence,
and patients a better understanding of their condition. Cortical Disarray Measurement (CDM®) software has been granted Breakthrough Device designation by the FDA.
Our insight into the micro-structure of the brain, can help clinicians track and accurately predict the
course or decline of neurodegenerative disease. CDM® measures are designed to detect altered quality of grey matter in AD patients. Our research into
MCI also supports using (CDM®) for identification of the early stages of Alzheimer’s disease.
Better patient care
Providing certainty in diagnosis
Differential diagnosis for Dementia
Accurately tracking decline
Proactive Brain Health